Trade BIOLASE - BIOL CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.14 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 4.54 |
Open* | 4.38 |
1-Year Change* | 1.62% |
Day's Range* | 4.26 - 4.58 |
52 wk Range | 0.30-9.24 |
Average Volume (10 days) | 272.89K |
Average Volume (3 months) | 11.95M |
Market Cap | 13.04M |
P/E Ratio | -100.00K |
Shares Outstanding | 35.58M |
Revenue | 46.82M |
EPS | -3.68 |
Dividend (Yield %) | N/A |
Beta | 1.42 |
Next Earnings Date | Mar 28, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jun 29, 2022 | 4.30 | -0.08 | -1.83% | 4.38 | 4.58 | 4.22 |
Jun 28, 2022 | 4.54 | 0.32 | 7.58% | 4.22 | 5.00 | 4.22 |
Jun 27, 2022 | 5.08 | 0.86 | 20.38% | 4.22 | 5.19 | 4.22 |
Jun 24, 2022 | 4.47 | 0.25 | 5.92% | 4.22 | 4.60 | 4.22 |
Jun 23, 2022 | 4.19 | 0.12 | 2.95% | 4.07 | 4.30 | 4.07 |
Jun 22, 2022 | 4.05 | -0.27 | -6.25% | 4.32 | 4.52 | 3.99 |
Jun 21, 2022 | 4.32 | 0.04 | 0.93% | 4.28 | 4.53 | 4.16 |
Jun 17, 2022 | 4.51 | 0.22 | 5.13% | 4.29 | 4.51 | 4.29 |
Jun 16, 2022 | 4.17 | -0.01 | -0.24% | 4.18 | 4.37 | 4.16 |
Jun 15, 2022 | 4.26 | 0.19 | 4.67% | 4.07 | 4.26 | 4.07 |
Jun 14, 2022 | 4.26 | 0.17 | 4.16% | 4.09 | 4.37 | 4.09 |
Jun 13, 2022 | 4.10 | -0.17 | -3.98% | 4.27 | 4.34 | 4.07 |
Jun 10, 2022 | 4.56 | -0.06 | -1.30% | 4.62 | 4.62 | 4.47 |
Jun 9, 2022 | 4.67 | 0.03 | 0.65% | 4.64 | 4.76 | 4.64 |
Jun 8, 2022 | 4.63 | 0.01 | 0.22% | 4.62 | 4.71 | 4.59 |
Jun 7, 2022 | 4.64 | 0.02 | 0.43% | 4.62 | 4.73 | 4.62 |
Jun 6, 2022 | 4.67 | 0.03 | 0.65% | 4.64 | 4.79 | 4.59 |
Jun 3, 2022 | 4.82 | 0.20 | 4.33% | 4.62 | 4.90 | 4.62 |
Jun 2, 2022 | 4.67 | 0.04 | 0.86% | 4.63 | 4.80 | 4.61 |
Jun 1, 2022 | 4.63 | -0.15 | -3.14% | 4.78 | 4.78 | 4.57 |
BIOLASE Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total revenue | 39.188 | 22.78 | 37.799 | 46.155 | 46.926 |
Revenue | 39.188 | 22.78 | 37.799 | 46.155 | 46.926 |
Cost of Revenue, Total | 22.659 | 16.607 | 23.511 | 29.26 | 31.8 |
Gross Profit | 16.529 | 6.173 | 14.288 | 16.895 | 15.126 |
Total Operating Expense | 52.605 | 41.316 | 53.42 | 67.04 | 64.964 |
Selling/General/Admin. Expenses, Total | 26.597 | 21.014 | 25.144 | 29.892 | 26.43 |
Research & Development | 6.048 | 3.695 | 4.765 | 5.203 | 6.229 |
Unusual Expense (Income) | -2.699 | 0 | 0 | 2.685 | 0.505 |
Operating Income | -13.417 | -18.536 | -15.621 | -20.885 | -18.038 |
Interest Income (Expense), Net Non-Operating | -2.676 | -2.38 | -2.278 | -0.568 | 0.605 |
Net Income Before Taxes | -16.093 | -16.701 | -17.899 | -21.453 | -17.433 |
Net Income After Taxes | -16.158 | -16.829 | -17.855 | -22.116 | 4.249 |
Net Income Before Extra. Items | -16.158 | -16.829 | -17.855 | -22.116 | 4.249 |
Net Income | -16.158 | -16.829 | -17.855 | -21.516 | -16.851 |
Total Adjustments to Net Income | -0.546 | -17.378 | 0 | 0 | -3.978 |
Income Available to Common Excl. Extra. Items | -16.704 | -34.207 | -17.855 | -22.116 | 0.271 |
Income Available to Common Incl. Extra. Items | -16.704 | -34.207 | -17.855 | -21.516 | -20.829 |
Diluted Net Income | -16.704 | -34.207 | -17.855 | -21.516 | -20.829 |
Diluted Weighted Average Shares | 5.90984 | 2.44544 | 0.92804 | 0.82352 | 0.59007 |
Diluted EPS Excluding Extraordinary Items | -2.82647 | -13.9881 | -19.2395 | -26.8554 | 0.45927 |
Diluted Normalized EPS | -3.12332 | -13.9881 | -19.2395 | -24.7362 | 1.01555 |
Total Extraordinary Items | 0.6 | -21.1 | |||
Other, Net | 0 | 4.215 |
Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
---|---|---|---|---|---|
Total revenue | 12.01 | 12.235 | 10.166 | 12.408 | 9.531 |
Revenue | 12.01 | 12.235 | 10.166 | 12.408 | 9.531 |
Cost of Revenue, Total | 9.565 | 7.094 | 5.437 | 7.502 | 4.689 |
Gross Profit | 2.445 | 5.141 | 4.729 | 4.906 | 4.842 |
Total Operating Expense | 19.661 | 17.29 | 14.372 | 16.838 | 12.188 |
Selling/General/Admin. Expenses, Total | 8.117 | 8.543 | 7.391 | 7.669 | 5.93 |
Research & Development | 1.979 | 1.653 | 1.544 | 1.542 | 1.54 |
Operating Income | -7.651 | -5.055 | -4.206 | -4.43 | -2.657 |
Interest Income (Expense), Net Non-Operating | -0.753 | -0.533 | -0.553 | -0.777 | -0.605 |
Net Income Before Taxes | -8.404 | -5.588 | -4.759 | -5.207 | -3.262 |
Net Income After Taxes | -8.387 | -5.611 | -4.776 | -5.279 | -3.276 |
Net Income Before Extra. Items | -8.387 | -5.611 | -4.776 | -5.279 | -3.276 |
Net Income | -8.387 | -5.611 | -4.776 | -5.279 | -3.276 |
Total Adjustments to Net Income | 0 | 0 | -0.217 | 0 | -0.009 |
Income Available to Common Excl. Extra. Items | -8.387 | -5.611 | -4.993 | -5.279 | -3.285 |
Income Available to Common Incl. Extra. Items | -8.387 | -5.611 | -4.993 | -5.279 | -3.285 |
Diluted Net Income | -8.387 | -5.611 | -4.993 | -5.279 | -3.285 |
Diluted Weighted Average Shares | 7.615 | 6.192 | 6.159 | 6.14228 | 6.07764 |
Diluted EPS Excluding Extraordinary Items | -1.10138 | -0.90617 | -0.81068 | -0.85945 | -0.54051 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -1.10138 | -0.90617 | -0.81068 | -0.84622 | -0.5374 |
Unusual Expense (Income) | 0 | 0 | 0.125 | 0.029 | |
Other, Net | 0 | 0 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 49.354 | 35.11 | 27.019 | 33.307 | 36.05 |
Cash and Short Term Investments | 29.972 | 17.564 | 5.789 | 8.044 | 11.645 |
Cash & Equivalents | 29.972 | 17.564 | 5.789 | 8.044 | 11.645 |
Total Receivables, Net | 4.238 | 3.059 | 8.76 | 11.112 | 10.124 |
Accounts Receivable - Trade, Net | 4.238 | 3.059 | 8.76 | 10.99 | 10.047 |
Total Inventory | 12.929 | 11.157 | 10.995 | 12.248 | 12.298 |
Prepaid Expenses | 2.012 | 3.018 | 1.163 | 1.591 | 1.732 |
Other Current Assets, Total | 0.203 | 0.312 | 0.312 | 0.312 | 0.251 |
Total Assets | 55.284 | 41.025 | 31.847 | 38.516 | 42.984 |
Property/Plant/Equipment, Total - Net | 2.784 | 2.758 | 1.469 | 1.975 | 3.674 |
Property/Plant/Equipment, Total - Gross | 10.833 | 10.422 | 10.791 | 10.319 | 11.1 |
Accumulated Depreciation, Total | -8.049 | -7.664 | -9.322 | -8.344 | -7.426 |
Goodwill, Net | 2.926 | 2.926 | 2.926 | 2.926 | 2.926 |
Intangibles, Net | 0 | 0 | 0 | 0 | 0 |
Other Long Term Assets, Total | 0.22 | 0.231 | 0.433 | 0.308 | 0.334 |
Total Current Liabilities | 13.844 | 11.223 | 25.779 | 15.967 | 13.37 |
Accounts Payable | 3.309 | 2.651 | 5.332 | 5.953 | 5.109 |
Accrued Expenses | 6.619 | 5.771 | 3.79 | 6.133 | 4.689 |
Notes Payable/Short Term Debt | 0 | 0 | 13.466 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | ||||
Other Current Liabilities, Total | 3.916 | 2.801 | 3.191 | 3.881 | 3.572 |
Total Liabilities | 30.076 | 30.997 | 27.505 | 27.427 | 13.724 |
Total Long Term Debt | 13.603 | 16.186 | 0 | 10.836 | 0 |
Capital Lease Obligations | |||||
Deferred Income Tax | 0.078 | 0.077 | 0.104 | ||
Other Liabilities, Total | 2.629 | 3.588 | 1.648 | 0.547 | 0.25 |
Total Equity | 25.208 | 10.028 | 4.342 | 11.089 | 29.26 |
Common Stock | 0.154 | 0.098 | 0.031 | 0.021 | 0.102 |
Additional Paid-In Capital | 293.177 | 261.573 | 235.594 | 228.43 | 224.91 |
Retained Earnings (Accumulated Deficit) | -267.534 | -251.376 | -234.547 | -216.692 | -195.176 |
Other Equity, Total | -0.623 | -0.385 | -0.701 | -0.67 | -0.576 |
Total Liabilities & Shareholders’ Equity | 55.284 | 41.025 | 31.847 | 38.516 | 42.984 |
Total Common Shares Outstanding | 6.14704 | 3.90654 | 1.25756 | 0.8429 | 0.81872 |
Long Term Debt | 13.603 | 16.186 | 0 | 10.836 | |
Redeemable Preferred Stock | 3.965 | ||||
Total Preferred Shares Outstanding | 0 | 0 | 0.07 | ||
Preferred Stock - Non Redeemable, Net | 0.034 | 0.118 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 43.783 | 49.354 | 52.654 | 55.34 | 57.749 |
Cash and Short Term Investments | 21.606 | 29.972 | 33.385 | 37.081 | 40.842 |
Cash & Equivalents | 21.606 | 29.972 | 33.385 | 37.081 | 40.842 |
Total Receivables, Net | 5.18 | 4.238 | 3.637 | 3.819 | 3.266 |
Accounts Receivable - Trade, Net | 5.18 | 4.238 | 3.637 | 3.819 | 3.266 |
Total Inventory | 14.611 | 12.929 | 14.062 | 12.715 | 11.877 |
Prepaid Expenses | 2.183 | 2.012 | 1.366 | 1.521 | 1.56 |
Other Current Assets, Total | 0.203 | 0.203 | 0.204 | 0.204 | 0.204 |
Total Assets | 50.242 | 55.284 | 58.514 | 61.249 | 63.484 |
Property/Plant/Equipment, Total - Net | 3.302 | 2.784 | 2.712 | 2.758 | 2.583 |
Property/Plant/Equipment, Total - Gross | 11.469 | 10.833 | 10.643 | 10.587 | 10.324 |
Accumulated Depreciation, Total | -8.167 | -8.049 | -7.931 | -7.829 | -7.741 |
Goodwill, Net | 2.926 | 2.926 | 2.926 | 2.926 | 2.926 |
Other Long Term Assets, Total | 0.231 | 0.22 | 0.222 | 0.225 | 0.226 |
Total Current Liabilities | 13.112 | 13.844 | 13.457 | 12.719 | 11.27 |
Accounts Payable | 4.643 | 3.309 | 3.597 | 3.502 | 3.072 |
Accrued Expenses | 5.167 | 6.619 | 4.929 | 5.174 | 5.386 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0.7 | 0 |
Other Current Liabilities, Total | 3.302 | 3.916 | 3.531 | 3.343 | 2.812 |
Total Liabilities | 29.642 | 30.076 | 28.192 | 27.993 | 29.968 |
Total Long Term Debt | 13.666 | 13.603 | 12.114 | 12.703 | 16.295 |
Long Term Debt | 13.666 | 13.603 | 12.114 | 12.703 | 16.295 |
Other Liabilities, Total | 2.864 | 2.629 | 2.621 | 2.571 | 2.403 |
Total Equity | 20.6 | 25.208 | 30.322 | 33.256 | 33.516 |
Preferred Stock - Non Redeemable, Net | 0 | 0.034 | 0.034 | 0.035 | 0.036 |
Common Stock | 0.155 | 0.154 | 0.153 | 0.151 | 0.149 |
Additional Paid-In Capital | 293.419 | 293.177 | 292.948 | 292.517 | 292.141 |
Retained Earnings (Accumulated Deficit) | -272.31 | -267.534 | -262.255 | -258.979 | -258.277 |
Other Equity, Total | -0.664 | -0.623 | -0.558 | -0.468 | -0.533 |
Total Liabilities & Shareholders’ Equity | 50.242 | 55.284 | 58.514 | 61.249 | 63.484 |
Total Common Shares Outstanding | 6.176 | 6.14704 | 6.13108 | 6.04944 | 5.97652 |
Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.4 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | -16.158 | -16.829 | -17.855 | -21.516 | -16.851 |
Cash From Operating Activities | -16.71 | -12.795 | -12.746 | -14.147 | -18.412 |
Cash From Operating Activities | 0.4 | 0.499 | 0.982 | 0.945 | 1.203 |
Deferred Taxes | 0.007 | -0.027 | -0.694 | ||
Non-Cash Items | 0.985 | 1.781 | 5.228 | 6.46 | 3.333 |
Cash Taxes Paid | 0.171 | 0.022 | 0.035 | 0.044 | 0.164 |
Cash Interest Paid | 1.771 | 1.881 | 1.784 | 0.023 | 0.001 |
Changes in Working Capital | -1.937 | 1.754 | -1.108 | -0.009 | -5.403 |
Cash From Investing Activities | -0.707 | -0.096 | -0.207 | -0.522 | -0.747 |
Capital Expenditures | -0.707 | -0.096 | -0.207 | -0.558 | -0.747 |
Other Investing Cash Flow Items, Total | 0 | 0.036 | 0 | ||
Cash From Financing Activities | 29.954 | 24.349 | 10.721 | 11.235 | 21.618 |
Financing Cash Flow Items | -1.135 | -3.049 | -0.954 | -1.222 | 0 |
Issuance (Retirement) of Stock, Net | 31.114 | 24.958 | 9.175 | 0.003 | 21.764 |
Issuance (Retirement) of Debt, Net | -0.025 | 2.44 | 2.5 | 12.454 | -0.146 |
Foreign Exchange Effects | -0.238 | 0.317 | -0.023 | -0.106 | 0.262 |
Net Change in Cash | 12.299 | 11.775 | -2.255 | -3.54 | 2.721 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.776 | -16.158 | -10.879 | -7.603 | -6.901 |
Cash From Operating Activities | -8.021 | -16.71 | -13.606 | -10.008 | -6.499 |
Cash From Operating Activities | 0.117 | 0.4 | 0.281 | 0.176 | 0.085 |
Deferred Taxes | 0 | ||||
Non-Cash Items | 0.42 | 0.985 | -1.035 | -1.461 | 1.118 |
Cash Taxes Paid | 0.026 | 0.171 | 0.154 | 0.13 | 0.01 |
Cash Interest Paid | 0.377 | 1.771 | 1.328 | 0.886 | 0.448 |
Changes in Working Capital | -3.782 | -1.937 | -1.973 | -1.12 | -0.801 |
Cash From Investing Activities | -0.304 | -0.707 | -0.396 | -0.311 | -0.008 |
Capital Expenditures | -0.304 | -0.707 | -0.396 | -0.311 | -0.008 |
Cash From Financing Activities | 0 | 29.954 | 29.886 | 29.811 | 29.825 |
Financing Cash Flow Items | 0 | -1.135 | -0.006 | -0.006 | -0.006 |
Issuance (Retirement) of Stock, Net | 0 | 31.114 | 29.917 | 29.841 | 29.831 |
Foreign Exchange Effects | -0.041 | -0.238 | -0.171 | -0.083 | -0.148 |
Net Change in Cash | -8.366 | 12.299 | 15.713 | 19.409 | 23.17 |
Issuance (Retirement) of Debt, Net | -0.025 | -0.025 | -0.024 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
BIOLASE Company profile
BIOLASE (BIOL) is a medical device company that manufactures dental laser systems. In 2012 the company changed its name from BIOLASE Technology to BIOLASE.
Founded in 1984, BIOLASE is headquartered in California. Its proprietary dental laser systems enable dentists to perform minimally invasive dental procedures.
Biolase’s Waterlase all-tissue dental laser systems can be used for cutting soft and hard tissues, and other micro-surgeries in soft tissues, pain therapy, teeth whitening and cosmetic procedures. Additionally, the Waterlase Express system minimises water usage by a significant level, and has the flexibility to treat infections like peri-implantitis and other periodontal diseases.
Along with the laser system, BIOLASE also sells products and accessories such as teeth whitening gel kits, flexible fibres and hand pieces.
The company went public on the Nasdaq stock exchange in 1993. BIOLASE, Inc. stock trades under the ticker symbol BIOL.
You can follow the BIOL share value and price chart live on Capital.com.
Industry: | Advanced Medical Equipment & Technology (NEC) |
27042 Towne Centre Drive
Suite 270
FOOTHILL RANCH
CALIFORNIA 92610
US
Income Statement
- Annual
- Quarterly
News

GBP/EUR forecast: Will the pound rise against the euro in 2023?
The British pound has been moving sideways against the Euro, yet can it regain momentum? Read on for a GBP/EUR forecast.
16:27, 24 March 2023
Shiba Inu price prediction: Can the meme coin build on recent gains?
What’s next for the Shiba Inu meme coin after a sluggish 2022 so far? Read more…
12:51, 24 March 2023
Who are the biggest bitcoin mining companies?
Bitcoin mining is big business, but who are the biggest bitcoin mining companies?
12:06, 24 March 2023
USD/PKR forecast: Will Pakistan’s rupee continue to fall?
The rupee has rebounded against the dollar in recent months, will this trend continue?
11:49, 24 March 2023
Amazon stock forecast: Where next for AMZN amid massive layoffs?
Amazon has been making tens of thousands of its workers redundant. Does this affect the market’s baseline Amazon stock forecast?
10:46, 24 March 2023
Sweatcoin price prediction: What is Sweatcoin?
Can Sweatcoin run to the front of the crypto pack?
15:19, 23 March 2023
Who owns the most bitcoin?
Want to know who owns the most bitcoin? Learn more about the biggest bitcoin whales.
14:54, 23 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com